InvestorsObserver
Sign Up Login

JAZZ Jazz Pharma Plc

$108.31 $1.21 (1.13%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

JAZZ Stock Analysis Overview

What this means: InvestorsObserver gives Jazz Pharma Plc (JAZZ) an overall rank of 37, which is below average. Jazz Pharma Plc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 37 means that 63% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

JAZZ Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

JAZZ Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

JAZZ Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

JAZZ Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

JAZZ Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

JAZZ Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

JAZZ Stock Analysis Overview

What this means: InvestorsObserver gives Jazz Pharma Plc (JAZZ) an overall rank of 37, which is below average. Jazz Pharma Plc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 37 means that 63% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full JAZZ report

JAZZ Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

JAZZ Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

JAZZ Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

JAZZ Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

JAZZ Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

JAZZ Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Jazz Pharma Plc (JAZZ) Analyst Forecast

JAZZ Price, Volume, Earnings, and Dividend Date

  • Last Price $108.31
  • Previous Close $107.10
  • Change $1.21
  • Open $107.15
  • Volume 128,284
  • Avg. Volume (100-day) 625,681
  • Market Cap 6,677,179,809
  • Days Range 107.15 - 108.56
  • 52-week Range 106.61 - 146.7
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 17.67
  • EPS 6.11
  • Earnings Date 05/08/24
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.849
  • PEG Ratio 1.53

Jazz Pharma Plc (JAZZ) Company Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharma Plc (JAZZ) Stock Chart

View Interactive JAZZ chart

My Watchlists

Top Stocks in Biotechnology